Multi-disciplinary Insights from the First European Forum on Visceral Myopathy 2022 Meeting

Abstract

Visceral myopathy is a rare, life-threatening disease linked to identified genetic mutations in 60% of cases. Mostly due to the dearth of knowledge regarding its pathogenesis, effective treatments are lacking. The disease is most commonly diagnosed in children with recurrent or persistent disabling episodes of functional intestinal obstruction, which can be life threatening, often requiring long-term parenteral or specialized enteral nutritional support. Although these interventions are undisputedly life-saving as they allow affected individuals to avoid malnutrition and related complications, they also seriously compromise their quality of life and can carry the risk of sepsis and thrombosis. Animal models for visceral myopathy, which could be crucial for advancing the scientific knowledge of this condition, are scarce. Clearly, a collaborative network is needed to develop research plans to clarify genotype–phenotype correlations and unravel molecular mechanisms to provide targeted therapeutic strategies. This paper represents a summary report of the first ‘European Forum on Visceral Myopathy’. This forum was attended by an international interdisciplinary working group that met to better understand visceral myopathy and foster interaction among scientists actively involved in the field and clinicians who specialize in care of people with visceral myopathy. Graphical Abstract

Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers

“…On the other hand, drug passage along the whole gastrointestinal tract represents a challenge for the stability of the therapy, which encounters harsh environments. Moreover, oral administration may prove ineffective in the presence of severe dysmotility, such as in the case of chronic intestinal pseudo-obstruction (CIPO) [ 346 , 347 ], especially in acute scenarios. In such conditions, other administration modes (such as the intravenous one, coupled with different drivers for drug release) could result in being more effective.…”